Translational Session
New Era for Repurposing and Development of CKD Therapies for People Living with Type 1 Diabetes
October 26, 2024 | 10:30 AM - 12:30 PM
Location: Ballroom 20A, Convention Center
Session Description
This session reviews the rationale and plan for ongoing trials of novel therapies for kidney protection for people with type 1 diabetes (T1D). Content regarding SGLT2 inhibitors includes discussion about the SUGARNSALT trial, the ASPIRE trial, and other dedicated trials of SGLT2 inhibitors in people with T1D. The incretin therapy discussion includes the REMODEL-T1D trial, and the nonsteroidal mineralocorticoid antagonist discussion includes the FINE-ONE trial.
Learning Objective(s)
- Explain the rationale for and results of trials with SGLT2 inhibitors for diabetic kidney disease in people with T1D
- Outline the rationale for and results of trials with nonsteroidal mineralocorticoid antagonists for diabetic kidney disease in people with T1D
- Articulate the rationale for and results of trials with incretins for diabetic kidney disease in people with T1D
- Summarize updates on pancreas and kidney-pancreas transplant in people with T1D
Learning Pathway(s)
- Diabetic Kidney Disease
- Kidney Biology and Physiology
Moderators
Presentations
- SGLT2 Inhibition and the Potential for Preventing Cardiorenal Complications in Type 1 Diabetes
10:30 AM - 11:00 AM
- Finerenone and Mineralocorticoid Receptor Antagonists in Type 1 Diabetes: Past, Present, and Future
11:00 AM - 11:30 AM
- Incretins and Kidney Protection in Type 1 Diabetes
11:30 AM - 12:00 PM
- Real-World Evidence of Efficacy and Safety of Adjunctive Therapies for Type 1 Diabetes
12:00 PM - 12:30 PM